Intellectia LogoIntellectia
Product
Resources
Stock
Crypto
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategy
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns

Resources

Learn
Blog
Earnings
Tutorial
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
StockCryptoPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ERAS
    4. >
  4. Valuation

Valuation

-
stocks logo
ERAS
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

Is ERAS Overvalued？

ERAS is now in the zone, suggesting that ERAS current forward PE ratio of -2.31 is considered compare with the five-year average of -4.96.
P/E
EV/EBITDA
P/S
P/B
P/E
bubble
P/E

ERAS Competitors Valuation Multiple

P/E
EV/EBITDA
P/S
P/E

P/E Multiple

Earnings Growth
Market Cap
stocks logo
ERAS.O
Erasca Inc
loss
Average P/E: 4.39
45.25%
401.47M
stocks logo
SIGA.O
SIGA Technologies Inc
4.96
Average P/E: 4.39
438.70%
407.72M
stocks logo
PHAT.O
Phathom Pharmaceuticals Inc
loss
Average P/E: 4.39
-73.87%
403.43M
stocks logo
CMPX.O
Compass Therapeutics Inc.
loss
Average P/E: 4.39
-3.79%
362.30M
stocks logo
AKBA.O
Akebia Therapeutics Inc
loss
Average P/E: 4.39
-23.82%
418.91M
stocks logo
EBS.N
Emergent BioSolutions Inc
3.82
Average P/E: 4.39
317.33M

ERAS Revenue Breakdown & PS Ratio Relation

Currency:USD
By Business
By Region
Composition ()
Name
Revenue
Percentage

ERAS FAQs

Is ERAS currently overvalued based on its P/E ratio?

According to the provided data, ERAS's 5-year historical average forward P/E ratio is -4.96. ERAS forward P/E ratio is -2.31, which is categorized as Overvalued.

What is the significance of the EV/EBITDA ratio for ERAS?

The EV/EBITDA ratio helps assess the company's valuation relative to its earnings before interest, taxes, depreciation, and amortization, providing a clearer picture of its operating performance.

What are the key indicators to watch for ERAS's financial performance?

Key indicators include valuation ratios (P/E, EV/EBITDA, P/FCF), revenue growth, and profitability metrics to assess overall financial health.

ERAS PE Ratio

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalued
5Y Average PE
-4.96
Current PE
-2.31
Overvalued PE
-2.39
Undervalued PE
-7.54

ERAS EV/EBITDA Ratio

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalued
5Y Average EV
-3.17
Current EV
0.25
Overvalued EV
0.76
Undervalued EV
-7.09

ERAS P/S Ratio

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalued
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

ERAS Competitors Valuation Multiple

P/E
EV/EBITDA
P/S
P/E

P/E Multiple

Earnings Growth
Market Cap
stocks logo
ERAS.O
Erasca Inc
loss
Average P/E: 4.39
45.25%
401.47M
stocks logo
SIGA.O
SIGA Technologies Inc
4.96
Average P/E: 4.39
438.70%
407.72M
stocks logo
PHAT.O
Phathom Pharmaceuticals Inc
loss
Average P/E: 4.39
-73.87%
403.43M
stocks logo
CMPX.O
Compass Therapeutics Inc.
loss
Average P/E: 4.39
-3.79%
362.30M
stocks logo
AKBA.O
Akebia Therapeutics Inc
loss
Average P/E: 4.39
-23.82%
418.91M
stocks logo
EBS.N
Emergent BioSolutions Inc
3.82
Average P/E: 4.39
317.33M

ERAS Revenue Breakdown & PS Ratio Relation

Currency:USD
By Business
By Region
Composition ()
Name
Revenue
Percentage

Free Financial AI Agent for Investment

Ask any investment related question and get answer instantly

At what price is ERAS undervalued？Is ERAS overvalued compared to its competitors？

ERAS FAQs

Is ERAS currently overvalued based on its P/E ratio?

According to the provided data, ERAS's 5-year historical average forward P/E ratio is -4.96. ERAS forward P/E ratio is -2.31, which is categorized as Overvalued.

What is the significance of the EV/EBITDA ratio for ERAS?

The EV/EBITDA ratio helps assess the company's valuation relative to its earnings before interest, taxes, depreciation, and amortization, providing a clearer picture of its operating performance.

What are the key indicators to watch for ERAS's financial performance?

Key indicators include valuation ratios (P/E, EV/EBITDA, P/FCF), revenue growth, and profitability metrics to assess overall financial health.

Free Financial AI Agent for Investment

Ask any investment related question and get answer instantly

At what price is ERAS undervalued？Is ERAS overvalued compared to its competitors？
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI Screener
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free